4,780.00
+0.63%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Torrent Pharmaceuticals
Its shares trade on NSE under the ticker TORNTPHARM.NS. It has been listed since 3 November 1994. In the fiscal year to 31 March 2026, it reported revenue of ₹139.80bn and net income of ₹21.63bn. At that date it held total assets of ₹443.12bn and shareholders' equity of ₹83.89bn.
Torrent Pharmaceuticals Ltd. engages in the research, development, manufacture, and marketing of generic pharmaceutical formulations. The company is headquartered in Ahmedabad, Gujarat. The firm is engaged in research, development, manufacturing and marketing of generic pharmaceutical formulations. The company operates in the therapeutic segments of cardiovascular (CV), gastrointestinal (GI), central nervous system (CNS), and vitamins minerals nutritionals (VMN). The company also has presence in therapeutic areas, such as anti-epileptic, anti-diabetic, anti-cancer, anti-acne, corticosteroids and cosmeceuticals. The company has developed complex formulations for global markets based on oral solids, injections, inhalation technologies, long-acting depot injections ophthalmic, nasal, semisolids for external applications and multi-particulate extended-release oral systems. The firm is developing various in-house new chemical entities (NCE) in the areas of metabolic, cardiovascular, gastrointestinal, dermatological and respiratory disorders. The company has a presence across more than 40 countries.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 3 Nov 1994
- Employees
- 12,910
- Website
- torrentpharma.com ↗
Leadership
Pay as last reported
- Shri. Samir MehtaExecutive Chairman of the Board, since 2001₹260.0m
- Shri. Sudhir MehtaChairman Emeritus, since 2003₹50.0m
- Shri. Sudhir MenonChief Financial Officer, Executive Director - Finance₹16.3m
- Mr. Chintan TrivediCompliance Officer, Company Secretary
- Mr. Aman MehtaWhole-time Director, since 2022₹65.9m
- Mr. Jinal MehtaNon-Executive Non-Independent Director
- Ms. Nayantara BaliIndependent Director₹6.7m
- Dr. Maurice ChagnaudIndependent Director₹6.3m
- Mr. Manish ChoksiIndependent Director₹4.3m
- Mr. Nikhil KhattauIndependent Director₹2.6m
- Ms. Ameera ShahIndependent Director₹4.9m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 81
- Environment
- 99
- Social
- 99
- Governance
- 44
- Direct emissions (scope 1)
- 15,294 t
- Energy emissions (scope 2)
- 76,268 t
- Women in the workforce
- 12%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Torrent Pharmaceuticals Ltd is an established and reliable pharmaceutical company with a long-standing presence in the market. With years of experience and a strong track record, the company has built a solid reputation for delivering high-quality products and services.
- Torrent Pharmaceuticals Ltd offers a wide range of pharmaceutical products across various therapeutic categories. This diversified product portfolio helps the company to cater to diverse customer needs and reduces the dependency on a single product or market segment.
- The company has a well-established research and development (R&D) division, which enables it to continuously innovate and develop new drugs. This strengthens its competitive edge and allows Torrent Pharmaceuticals Ltd to stay ahead in the market by introducing novel and effective treatments.
Weaknesses
- Torrent Pharmaceuticals Ltd relies heavily on patents for its revenue generation. The expiration of patents can lead to generic competition and potentially impact the company's financial performance. This vulnerability to patent expiry is a weakness that needs to be managed effectively.
- Although the company has a strong domestic presence, its global footprint is relatively limited. This lack of international reach may restrict opportunities for growth and expansion in emerging markets. Torrent Pharmaceuticals Ltd needs to explore strategies to enter new markets and increase its global presence.
Opportunities
- The pharmaceutical industry is experiencing significant growth worldwide, driven by an aging population, increasing healthcare expenditure, and advancements in medical technology. Torrent Pharmaceuticals Ltd can capitalize on this opportunity by introducing new products and expanding its market share.
- The demand for generic drugs is rising globally due to their lower cost compared to branded drugs. Torrent Pharmaceuticals Ltd can leverage this trend by expanding its generic drug portfolio and capturing a larger market share. This can lead to improved profitability and revenue growth.
Threats
- The pharmaceutical industry is highly competitive, with numerous players vying for market share. Torrent Pharmaceuticals Ltd faces the risk of intense competition from both domestic and international pharmaceutical companies. Continuous innovation, product differentiation, and strong marketing strategies are essential to mitigate this threat.
- The pharmaceutical industry is subject to strict regulations and compliance requirements. Any non-compliance can result in penalties and reputational damage. Torrent Pharmaceuticals Ltd needs to ensure strict adherence to regulatory standards and invest in robust compliance mechanisms to avoid any legal or regulatory issues.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.